+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Premenstrual Syndrome - Pipeline Review, H2 2019

  • ID: 4894191
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 37 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Asarina Pharma AB
  • MetVital Inc
  • MORE
Premenstrual Syndrome - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Premenstrual Syndrome - Pipeline Review, H2 2019, provides an overview of the Premenstrual Syndrome (Women's Health) pipeline landscape.

Premenstrual syndrome (PMS) is a collection of physical and emotional symptoms related to a woman's menstrual cycle. Premenstrual syndrome has a wide variety of symptoms, including mood swings, tender breasts, food cravings, fatigue, irritability and depression.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Premenstrual Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Premenstrual Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premenstrual Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively.

Premenstrual Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Premenstrual Syndrome (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Premenstrual Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Premenstrual Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Premenstrual Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Premenstrual Syndrome (Women's Health)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premenstrual Syndrome (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premenstrual Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Asarina Pharma AB
  • MetVital Inc
  • MORE
Introduction
Report Coverage
Premenstrual Syndrome - Overview
Premenstrual Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Premenstrual Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premenstrual Syndrome - Companies Involved in Therapeutics Development
Asarina Pharma AB
MetVital Inc
Pherin Pharmaceuticals Inc
Transdermal Delivery Solutions Corp
Premenstrual Syndrome - Drug Profiles
(estrogen + progesterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anhydrous enol oxaloacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PH-80PMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Antagonize GABAA Receptor for PMDD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Antagonize GABAA Receptor for PMDD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premenstrual Syndrome - Dormant Projects
Premenstrual Syndrome - Product Development Milestones
Featured News & Press Releases
Aug 15, 2019: Last Patient In for landmark PMDD study
Aug 30, 2018: Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm
Jul 09, 2018: Chief Medical Officer appointed for clinical trials of world’s first therapy targeting both PMDD and menstrual migraine
Apr 24, 2018: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD
Apr 24, 2018: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD
Apr 06, 2018: Asarina Pharma announces the start of a clinical Phase IIB study in patients with premenstrual dysphoric disorder
Apr 04, 2018: Asarina Pharma starts recruiting patients for Phase IIB clinical trial of Sepranolone, the world’s first treatment specifically targeting PMDD (premenstrual dysphoric disorder), the severest form of PMS
Apr 03, 2017: Asarina Pharma Phase IIa clinical study with Sepranolone in premenstrual dysphoric disorder meets primary endpoint.
Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)
Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder
Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms
May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Premenstrual Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Premenstrual Syndrome - Pipeline by Asarina Pharma AB, H2 2019
Premenstrual Syndrome - Pipeline by MetVital Inc, H2 2019
Premenstrual Syndrome - Pipeline by Pherin Pharmaceuticals Inc, H2 2019
Premenstrual Syndrome - Pipeline by Transdermal Delivery Solutions Corp, H2 2019
Premenstrual Syndrome - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Premenstrual Syndrome, H2 2019 7
Number of Products under Development by Companies, H2 2019 8
Number of Products by Targets, H2 2019 10
Number of Products by Stage and Targets, H2 2019 11
Number of Products by Mechanism of Actions, H2 2019 12
Number of Products by Stage and Mechanism of Actions, H2 2019 13
Number of Products by Routes of Administration, H2 2019 14
Number of Products by Stage and Routes of Administration, H2 2019 15
Number of Products by Stage and Top 10 Molecule Types, H2 2019 16
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Asarina Pharma AB
  • MetVital Inc
  • Pherin Pharmaceuticals Inc
  • Transdermal Delivery Solutions Corp
Note: Product cover images may vary from those shown
Adroll
adroll